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Loss of PHF6 leads to aberrant 
development of human neuron‑like 
cells
Anna Fliedner1, Anne Gregor1, Fulvia Ferrazzi1, Arif B. Ekici1, Heinrich Sticht2 & 
Christiane Zweier1,3*
Pathogenic variants in PHD finger protein 6 (PHF6) cause Borjeson–Forssman–Lehmann syndrome 
(BFLS), a rare X‑linked neurodevelopmental disorder, which manifests variably in both males and 
females. To investigate the mechanisms behind overlapping but distinct clinical aspects between 
genders, we assessed the consequences of individual variants with structural modelling and molecular 
techniques. We found evidence that de novo variants occurring in females are more severe and result 
in loss of PHF6, while inherited variants identified in males might be hypomorph or have weaker 
effects on protein stability. This might contribute to the different phenotypes in male versus female 
individuals with BFLS. Furthermore, we used CRISPR/Cas9 to induce knockout of PHF6 in SK‑N‑BE 
(2) cells which were then differentiated to neuron‑like cells in order to model nervous system related 
consequences of PHF6 loss. Transcriptome analysis revealed a broad deregulation of genes involved in 
chromatin and transcriptional regulation as well as in axon and neuron development. Subsequently, 
we could demonstrate that PHF6 is indeed required for proper neuron proliferation, neurite outgrowth 
and migration. Impairment of these processes might therefore contribute to the neurodevelopmental 
and cognitive dysfunction in BFLS.
Variants in the gene encoding PHD finger protein 6 (PHF6 [MIM: 300414]) have been identified to cause 
Borjeson–Forssman–Lehmann syndrome (BFLS [MIM: #301900]), an X-linked syndromic neurodevelopmental 
disorder (NDD)1,2, affecting both male and female individuals. In males, it is characterized by mild to severe 
intellectual disability (ID), epilepsy, a distinct facial gestalt, obesity and  hypogonadism1,3,4. In these families, 
female carriers are usually unaffected or present with mild symptoms,  only2,3. Recently, de novo variants in PHF6 
were identified in affected females with NDDs, partly overlapping with BFLS in males but additionally with very 
distinct phenotypic  aspects4–7. They presented with mild to severe ID, a characteristic facial gestalt, finger and 
toe anomalies, irregularly shaped teeth and  oligodontia4,5.
The mutational spectrum encompasses truncating and missense variants in PHF6 in both genders, thus not 
allowing obvious delineations of a genotype–phenotype correlation. Linear skin pigmentation in many of the 
affected females in combination with skewed X-inactivation in blood versus random X-inactivation in fibroblasts 
pointed to a functional mosaicism in these  individuals4. This might contribute to the manifestation of a relatively 
severe, distinct NDD in females.
Phf6 expression levels are particularly high in the developing mouse brain, and it is also highly expressed in 
developing facial structures (pharyngeal arches and the nasal process) and in limb  buds8. The expression pattern 
is therefore in line with the neurodevelopmental phenotype, facial dysmorphism and finger/toe anomalies in 
affected human  individuals8.
PHF6 encodes a protein with two extended atypical PHD-like zinc finger domains (ePHD), two nuclear and 
one nucleolar localization  sequences2. Due to the DNA-binding  domains9 and its co-localization with tran-
scriptionally active euchromatin in the  nucleus8, a role as transcriptional regulator and/or chromatin remodeler 
has been suggested (reviewed  in10). Furthermore, PHF6 functions as a histone reader recognizing H2BK12 
acetylation via the extended part of its C-terminal PHD, and additionally as a histone writer/E3 ubiquitin 
ligase by triggering H2BK120 ubiquitination through the extended part of N-terminal ePHD during trophec-
toderm  development11.Several protein-interaction partners of PHF6 have been identified, most of them indeed 
involved in transcriptional and chromatin regulation. Interaction of PHF6 with the PAF1 transcription elongation 
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 complex12,13 might play a role in driving neuronal  migration12, and by interaction with upstream binding fac-
tor  UBTF12,14 (MIM: 600673), it might be involved in ribosomal DNA  transcription14,15. In addition, PHF6 was 
demonstrated to interact with histone deacetylase 1 (HDAC1 [MIM: 601241])16 and the ATP-dependent chro-
matin remodelling NuRD  complex16. More recently it was shown that PHF6 is required to maintain a precise 
chromatin landscape in leukemia  cells17. It is also regulating transcriptional networks by its chromatin-binding 
capacities, dependent on the nutritional  state18.
Furthermore, a role of PHF6 deficiency in impaired cell proliferation, cell cycle arrest and increased DNA 
damage at the rDNA locus has been controversially  discussed14,15,17,19.
We could now show that both truncating and missense variants in females result in loss of PHF6 while struc-
tural modelling indicated that variants identified in males might be less severe. Furthermore, RNA sequencing 
on human neuron-like cells upon CRISPR/Cas9 mediated knockout of PHF6 revealed a broad deregulation of 
genes enriched for chromatin organization, transcription, neuron generation and nervous system development. 
Analysis of these PHF6 knockout cells showed altered neurite outgrowth, proliferation and migration. Our 
observations therefore implicate these processes in the pathomechanism of BFLS.
Results
Predicted destabilizing effects of missense variants in PHF6. In male and female individuals with 
BFLS both truncating and missense variants in PHF6 have been reported as  pathogenic1,4,6,7,20–29, though mis-
sense variants seem to be significantly more frequent in males (13 independent families versus 1 individual) 
and truncating variants (7 independent families versus 11 cases/families) more frequent in females (p < 0.005, 
Fisher’s exact test).
From literature we retrieved nine missense variants in PHF6 identified in  males2,6,21,23,24 and one missense 
variant identified in a female with  BFLS4. Apart from two variants located close to the N-terminal ePHD, all 
missense variants were residing in either the N-terminal or the C-terminal ePHD (Fig. 1a). Variants within 
domains were assessed regarding their consequences on PHF6 protein structure using the program  VIPUR30. 
Interestingly, missense variants from males that where located in the N-terminal ePHD had very high scores 
above 0.9, indicating strong destabilizing effects on the protein structure, while missense variants from males 
located in the C-terminal ePHD had significantly lower scores, indicating less severe effects on protein structure 
(Fig. 1a,b). In contrast, the only missense variant reported in females, so far, is located in the C-terminal ePHD 
and had a very high score of 0.98, indicating a stronger destabilizing effect on the protein structure than the 
variants from males residing in the same ePHD (Fig. 1a,b).
In silico analyses therefore predict variable destabilizing effects of missense variants dependent on their 
location.
Localization differences of mutant PHF6. To investigate if PHF6 variants might result in altered sub-
cellular localization in vitro, we investigated the consequences of two missense variants identified in males [one 
from each ePHD, respectively (c.266G>T, p.(Gly89Val); c.940A>G, p.(Ile314Val))6,23] and the only missense 
variant reported in females (c.914G>T, p(Cys305Phe))4 in the C-terminal ePHD. Additionally, we analyzed 
one C-terminal truncating variant reported in males (c.1024C>T, p.(Arg342*))2 and two truncating variants 
reported in females in the C-terminal ePHD (c.677delG, p.(Gly226Glufs*53); c.955C>T, p.(Arg319*))4 (Fig. 1a). 
We overexpressed HA-tagged wildtype or mutant PHF6 in HEK-293 cells. As reported  before2, wildtype PHF6 
showed an even distribution in nucleoplasm and nucleolus, as demonstrated by co-staining with nucleolin (NCL) 
(Fig. 1c). The two missense and one truncating variants identified in males behaved similar to the wildtype, with 
PHF6 and NCL co-localizing in the nucleolus (Fig. 1c). Additionally, protein expression levels were compara-
ble to wildtype expression for the missense variant in the C-terminal ePHD and slightly reduced for the mis-
sense variant in the N-terminal ePHD (46% residual protein) or the truncating variant (88% residual protein) 
Figure 1.  Overexpression analysis of variants in PHF6 from females vs males. (a) Protein scheme of PHF6 
(Q8IWS0) with all missense variants previously published in male and female  individuals2,4,6,21,23,24 as well 
as three selected truncating  variants2,4 analysed via immunofluorescence coloured in red. Analysed variants 
(immunofluorescence) are printed in bold. Coding domains (according to  uniprot91) are displayed in colour. 
NLS nuclear localization domain, NoLS nucleolar localization domain. (b) Table including all published 
missense variants occurring in male and female individuals, their VIPUR score, their localization in regard 
to ePHD and their origin (inherited/de novo). Variants p.(Met1Tyr) and p.(Ser138Cys) do not reside in a 
domain and cannot be modelled. Analysed variants (immunofluorescence) are printed in bold. ePHD extended 
atypical PHD-like zinc finger domain, 1 = N-terminal, 2 = C-terminal. (c) Immunofluorescence of HEK-293 
cells transiently transfected with HA-tagged wildtype or mutant PHF6 co-stained with nucleolin (NCL). While 
wildtype PHF6 was expressed in the nucleoplasm as well as the nucleolus co-localizing with NCL, all three 
variants occurring in females led to an accumulation of PHF6 into aggregates, partly co-localizing with NCL. 
The truncating variant c.677delG (p.(Gly226Glufs*53)) resulted in small and more aggregates in the nucleus, 
and the two variants in the C-terminal ePHD resulted in large PHF6 aggregates while the expression of aberrant 
PHF6 in the nucleoplasm is reduced. In contrast, the three variants occurring in males resembled the wildtype 
with PHF6 expression in both the nucleoplasm and the nucleolus, co-localizing with NCL. Per variant, at 
least 40 cells were analyzed. Scale bar depicts 20 µm. Cells were stained with rabbit anti-HA (H6908, Sigma-
Aldrich, 1:75) and mouse anti-nucleolin (39–6400, Thermo Fisher Scientific, 1:200). (d) Quantification of 
nuclear aggregates. The number of cells with or without aberrant large or small PHF6 aggregates in the nucleus 
was quantified for each variant and the wildtype. At least 40 cells were evaluated for each variant. ♀, variant 
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(Supplementary Fig. S1). In contrast, one missense and two truncating variants identified in females were still 
expressed in the nucleus, but accumulated in aggregates (Fig. 1c). Aggregates resulting from the early truncating 
p.(Gyl226Glyfs*53) variant appeared rather small. In cells overexpressing the more C-terminal truncating and 
the missense variant, larger aggregates were observed, while expression of mutant PHF6 in the nucleoplasm was 
reduced. Also co-localization with NCL was more variable, with the early truncating variant partly co-localizing 
with NCL in the nucleolus, and the more C-terminal variant barely or not co-localizing with NCL (Fig. 1c). More 
than 80% of analyzed cells (at least 40 cells/variant) presented with the same aggregate expression pattern. Quan-
tification is provided in Fig. 1d. Furthermore, mutant PHF6 protein levels were markedly reduced in comparison 
to wildtype (3–7% residual protein), suggesting impairment of either mRNA stability, transcription, translation 
or protein stability (Supplementary Fig. S1).
Taken together, overexpression of PHF6 carrying variants identified in females led to altered subcellular 
localization of PHF6 with formation of aggregates and markedly decreased protein levels, while PHF6 containing 
variants identified in males behaved more similar to wildtype PHF6. Though tested in a rather “artificial” situation 
by overexpression, variants identified in females or males behaved differently with more severe consequences 
for “female” variants.
Pathogenic variants in females result in loss of PHF6. Fibroblast cultures were available from three 
previously published female individuals with de novo variants in PHF6 [duplication of exons 4 and 5; missense 
variant c.914G>T (p.(Cys305Phe)); truncating variant c.955C>T (p.(Arg319*))]4. Fibroblasts of male individu-
als with BFLS were not available for this study. As the X-inactivation in fibroblasts had been random in the 
investigated females (in contrast to skewed X-inactivation in blood)4, we were able to assess both the mutant and 
wildtype PHF6 allele. Utilizing immunofluorescence, western blot and Sanger sequencing, we found that only 
wildtype gene and protein were expressed in fibroblasts of the three individuals (Fig. 2). Fibroblasts of affected 
individuals lacked PHF6 expression in 40–60% of a minimum of 60 assessed cells, respectively (Fig.  2a,b). 
Sequencing genomic DNA and cDNA from fibroblasts of individuals with the missense and truncating variants 
revealed that only the wildtype and not the mutant allele was present on RNA level, thus indicating nonsense-
mediated mRNA decay (NMD) for the truncating variant (Fig. 2c). As the duplication of exons 4 and 5, if in 
tandem, is predicted to result in frameshifting, a truncating effect with nonsense-mediated mRNA is likely as 
well. As NMD is less common for missense  variants31, we also considered other mechanisms of mRNA degrada-
tion such as micro RNA (miRNA) mediated  decay32. Indeed, variant c.914G>T was predicted to create two novel 
miRNA binding sites at this locus (Supplementary Fig. S2), providing a potential explanation for the loss of the 
mutant allele on RNA level. Nevertheless, the exact mechanism resulting in reduced expression of PHF6 carry-
ing the missense variant remains currently elusive.
In accordance with mRNA expression levels, western blot analysis on fibroblasts showed a reduction of protein 
levels to 50–70% in all three affected individuals, respectively. Western blots were normalized to tubulin levels 
(Fig. 2d,e, Supplementary Fig. S3). In contrast to aggregation of mutant PHF6 in vitro, all three tested PHF6 
variants ex vivo appeared to result in loss of protein, independent from their type (missense, truncating, intra-
genic duplication), indicating a common loss-of-function mechanism in females with BFLS.
Broad deregulation of genes in PHF6 knockout cells. Based on the observation of PHF6 loss in fibro-
blasts from affected female individuals, we considered knockout (KO) of PHF6 a more suitable model for the 
female form of BFLS in a neuronal context than overexpression of the mutant protein. Utilizing CRISPR/Cas9 
we generated PHF6 KO in neuroblastoma SK-N-BE (2) cells. KO was confirmed by sequencing and western blot 
analysis in three different cell lines (Supplementary Fig. S4). Subsequently, these cells were differentiated into 
neuron-like cells on which we performed bulk RNA sequencing. Transcriptome analysis in three independent 
controls and three independent PHF6 KO lines (targeted either exon 2 or 9, Supplementary Fig. S5) revealed 
a broad deregulation with 1,338 differentially expressed genes. 626 of those were upregulated, and 712 were 
downregulated with an adjusted p value < 0.05 (FDR corrected) (Supplementary Table S1). Controls and KO 
cells clustered readily within their group (Fig. 3a, Supplementary Fig. S5). The top five terms of Gene Ontology 
(GO) term  analysis33–35 in upregulated genes included skeletal system development, negative regulation of cel-
lular or biological processes, regulation of RNA metabolic processes, and regulation of canonical Wnt-signaling 
(Fig. 3b). Downregulated genes were enriched for genes playing a role in (regulation of) multicellular organismal 
processes, nucleic acid metabolic processes, macromolecule metabolic processes and gene expression (Fig. 3c). 
Additionally, deregulated genes were significantly (adjusted p value < 0.01) enriched for GO terms such as DNA-
templated transcription and chromosome organization (Supplementary Table S1).
This prompted us to compare deregulated genes (either up- or downregulated) upon PHF6 KO with genes 
deregulated after dosage alteration of a known chromatin remodeler or transcription factor. We retrieved pub-
lished  datasets36–39 containing gene expression changes caused by KO or knockdown (KD) of several genes with 
a clinical or possibly functional overlap to PHF6. KDM5C (MIM: 314690) (Kdm5c KO mouse, amygdala and 
frontal  cortex36) is a demethylase which acts as a transcriptional repressor through the REST  complex40. Vari-
ants in KDM5C are implicated in an X-linked NDD with mild to severe ID, epilepsy, short statue, mild facial 
dysmorphism including large ears, and hypogonadism (MRXSJ [MIM #300534]), partly mirroring the phe-
notype observed in males with  BFLS41–44. Additionally, KDM5C also contains two PHD zinc finger  domains42. 
The BAF complex (Baf155/Baf170 dKO mouse, pallium of E17.5  embryos37) is an ATP dependent chromatin 
remodeling  complex45. Variants in several subunits of the BAF complex are causative for Coffin–Siris syndrome 
(CSS [MIM #135900, #614607, #614608, #614609, #616938, #617808, #618362, #618779 ]), a NDD with mul-
tiple  anomalies46,47, phenotypically overlapping with BFLS due to de novo variants in PHF6 in young female 
 individuals5. BMI1 (MIM: 164831) (Bmi1 KO mouse, whole  brain38) represents a major component of the 
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Figure 2.  Variants in PHF6 in female individuals lead to a loss of protein. In fibroblasts of female individuals with 
variants in PHF6, only the wildtype PHF6 allele was expressed. (a) Immunofluorescence of fibroblasts of three 
individuals with either a duplication of exons 4 and 5, a missense variant c.914G>T (p.(Cys305Phe), or a truncating 
variant c.955C>T (p.(Arg319*) and one control individual. In the control, PHF6 expression could be observed in all 
fibroblast cells. In affected individuals, expression of PHF6 was present in only 50% of cells. Scale bar represents 20 µm. 
Cells were stained with rabbit polyclonal anti-PHF6 antibody (HPA001023, Sigma-Aldrich, 1:50). (b) Numerical 
analysis of fibroblasts with variants in PHF6 and controls. Affected individuals showed expression of PHF6 in 30–50% 
of cells, respectively. For each individual, at least 63 cells were evaluated. (c) Sanger sequencing of genomic DNA 
(gDNA) and of cDNA from RNA of affected individuals. In the individuals with a missense or a truncating variant 
respectively, both wildtype and mutant allele could be observed on gDNA level. On cDNA level, only the wildtype 
allele was present, thus indicating nonsense mediated mRNA decay. (d) Exemplary western blot from fibroblasts of 
control and affected individuals stained for PHF6 (Santa Cruz Biotechnology, sc-365237, 1:500) and Tubulin (ab7291, 
abcam, 1:10,000) as a housekeeping gene. PHF6 levels in patient fibroblasts were decreased. Grouped blots were 
cropped from different blots. Uncropped blots can be found in Supplementary Fig. S2. (e) Graphical analysis of three 
western blot replicates indicating 50%-70% of remaining PHF6 protein in patient fibroblasts. Error bars depict the 
standard deviation. Asterisks indicate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 3.  Transcriptome analysis of neuron-like PHF6 KO cells. (a) Heatmap displaying 1,338 deregulated genes 
between differentiated SK-N-BE (2) PHF6 KO and control cells with adjusted p value < 0.05 (FDR corrected). 626 genes 
were upregulated, and 712 were downregulated in PHF6 KO cells. Heatmap was created using the pheatmap package 
v.1.0.1286 applying the standard settings (complete linkage method for hierarchical clustering for both columns and 
rows, scaling for rows). Blue = downregulated; red = upregulated. (b,c) Gene Ontology (GO) term analysis of (b) 
upregulated and (c) downregulated genes depicting the top five GO terms for biological processes. (d) Comparison of 
deregulated genes after KO/KD of common chromatin remodelers and transcription factors with deregulated genes 
after PHF6 KO divided in up- and downregulated genes. Deregulated genes after KO/KD of either KDM5C (Kdm5c 
KO mouse model, RNA sequencing of amygdala and frontal cortex)36, the BAF complex (dKO Baf155/Baf170 mouse 
model, RNA sequencing of the pallium of E17.5 embryos)37, BMI1 (Bmi1 KO mouse model, RNA sequencing of 
whole brain)38 or TCF4 (TCF4 KD SH-SY5Y neuroblastoma cells)39 expressed a highly significant overlap with up- 
and downregulated genes after PHF6 KO. Darkness of color correlates with significance. (e) Significant GO terms 
involved in neuron development and axonogenesis (p < 0.005). (f) Venn diagram depicting that deregulated genes were 
significantly enriched for genes implicated in neurodevelopmental disorders (NDDs). Asterisks indicate statistical 
significance (*p < 0.05, **p < 0.01, ***p < 0.001).
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polycomb group complex 1 (PcG 1), which acts as an epigenetic  repressor48,49. As our set of deregulated genes 
after PHF6 KO contained a large number of homeobox (Hox) genes (HOXA1-3 [MIM: 142955, 604685, 142954], 
HOXA7 [MIM: 142950], HOXB2 [MIM: 142967] and HOXC9 [MIM: 142971], Supplementary Table S1), we 
decided to investigate the overlap with deregulated genes after Bmi1 KO, since the main targets of PcGs are Hox 
 genes50,51. Lastly, we chose TCF4 (MIM: 602272) (TCF4 KD SH-SY5Y neuroblastoma cells)39, a transcription 
factor with a major role in nervous system  development52 and implicated in severe NDD Pitt-Hopkins syndrome 
(MIM: #610954). It promotes differentiation of neurons, thus being a good fit for differentiation of SK-N-BE (2) 
cells into neuron-like  cells53. In addition, we used a so far unpublished list of deregulated genes in individuals 
with pathogenic variants in TCF4 (patient blood cells) (Supplementary Table S1).
Deregulated genes upon PHF6 KO were significantly overlapping with deregulated gene sets upon KO of 
either a Baf complex subunit or Bmi1 (Table 1). Overlapping genes between Baf complex KO and PHF6 KO 
were significantly enriched for genes involved in neuron generation, development and differentiation as well as 
regulation of nervous system development (adjusted p value < 0.05, Supplementary Table S1). Overlapping genes 
between Bmi1 KO and PHF6 KO were enriched for genes involved in axon development, axon guidance and 
positive regulation of transcription by RNA polymerase II (RNAPII) (adjusted p value < 0.05, Supplementary 
Table S1). In addition, deregulated genes upon PHF6 KO significantly overlapped with deregulated genes after 
Kdm5c KO and with deregulated genes after TCF4 dosage alterations in neuroblastoma cells but not in human 
blood after correction for multiple testing (Table 1). Overlapping deregulated genes between Kdm5c KO and 
PHF6 KO were enriched for synaptic signaling (adjusted p value < 0.05). Overlapping deregulated genes between 
TCF4 KD and PHF6 KO were enriched for genes involved in regulation of nervous system development, neu-
rogenesis and cell migration (adjusted p value < 0.05). (Fig. 3d, Supplementary Table S1). This would be in line 
with PHF6 acting in chromatin and transcriptional regulation, especially during neuron and axon development.
Furthermore, also downregulated genes after PHF6 KO were enriched for GO terms such as neuron develop-
ment, synaptic signaling, axon development and generation of neurons (Fig. 3e), suggesting a possible deregu-
lation of neuron development contributing to the neurodevelopmental and cognitive phenotypes in BFLS. In 
accordance, the set of deregulated genes after PHF6 KO was significantly (adjusted p value < 0.05) enriched for 
known NDD associated genes. Of 1,336 confirmed ID genes (SysID  database54, June 2020), 1,250 were expressed 
in differentiated SK-N-BE (2) cells, and 92 were contained in the deregulated gene set. This is significantly higher 
than the expected number of 72 genes by chance (p value < 0.05) (Fig. 3f, Supplementary Table S1). Overlapping 
genes between the SysID data base and PHF6 KO were enriched for genes involved in synaptic vesicle cycle, 
synaptic signaling, neuron projection development and generation of neurons. Genes involved in neuron pro-
jection development included ACTB (MIM: 102630) and MAP1B (MIM: 157129), both important for neurite 
 cytoskeleton55.
Additionally, KDM5C we compared our deregulated gene set with published lists of deregulated genes in 
murine cerebral  cortex56 or agouti-related peptide (AgRP)  neurons18 upon PHF6 KO. We found that 18 genes 
were overlappingly deregulated in murine cerebral cortex and our neuron-like cells, and that 38 genes were 
overlappingly deregulated in murine AgRP neurons and our neuron-like cells. The overlap in both cases was 
significantly higher than by chance (cerebral cortex: p < 0.05, expected: 10.75; AgRP neurons: p < 0.005, expected: 
23.57) (Supplementary Table S1). As, however, there was no overlap between deregulated genes from cerebral 
cortex and AgRP neurons, possibly due to different cell types, conclusions on specific target genes are limited.
Impaired neurite outgrowth, proliferation and migration in PHF6 KO cells. Following up on 
enriched GO terms such as axon development, we assessed differentiating PHF6 KO and WT SK-N-BE (2) cells 
for neurite outgrowth by measuring the total length of their protrusions and length and number of primary and 
secondary neurites. Cells with PHF6 KO had significantly (p value < 0.01) increased total neurite length com-
pared to control cells (Fig. 4a,b), and the number of primary neurites was significantly increased (p value < 0.05) 
(Fig. 4b). Length of the longest primary neurite (axon) was also increased (p value < 0.001) (Fig. 4a,c, Supple-
mentary Fig. S6a). While most of wild type cells rarely developed more than two primary neurites, some of the 
PHF6 KO cells had up to five primary neurites (Supplementary Fig. S6b). The number and length of secondary 
neurites was not altered in PHF6 KO cells compared to controls (Supplementary Fig. S6c).
We also assessed the effect of PHF6 KO on cell proliferation using an XTT-assay. We did not observe a pro-
liferation difference between KO and WT SK-N-BE (2) cells under normal culture conditions (Supplementary 
Table 1.  Overlap of deregulated genes in PHF6 KO SK-N-BE (2) cells with other deregulated gene sets. 
Testing for statistical significance was performed using hypergeometric testing and correcting for multiple 
testing using the Benjamini–Hochberg procedure. Amy amygdala, FC frontal cortex.
Overlap of PHF6 KO 
SK-N-BE (2) cells with
Number of 
downregulated genes Adjusted p value (down)
Number of upregulated 
genes Adjusted p value (up)
BAF  complex37 30 0.009733 28 0.008548
BMI138 85 0.000549 73 0.001861
KDM5C  Amy36 27 0.001 16 0.052961
KDM5C  FC36 34 0.000422 26 0.00385
TCF4 (SH-SY5Y)39 33 0.035384 32 0.029234
TCF4 (human blood) 6 0.15882 11 0.055686
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Fig. S7). However, during differentiation when kept in the presence of retinoic acid and caffeic acid, PHF6 KO 
cells exhibited a significant slower proliferation starting at day eight (p value < 0.01 on day 8, p value < 0.001 on 
day 10) (Fig. 4c). Firstly, we explored if that might be due to cell cycle changes. We performed FACS (fluorescence 
activated cell sorting) experiments to determine the percentage of cells in G1, S or G2/M phase, respectively. This 
did not reveal any significant changes in distribution between cell cycle phases (Supplementary Figs. S8a, S9). 
Next, we investigated if PHF6 KO cells might show an increase in differentiation. We performed FACS staining 
of cells with Ki67, a marker for cells which are not in the G0  phase57. Neither control nor PHF6 KO cells were 
negative for Ki67 staining (< 2%), indicating that only a minor fraction of the cells were fully differentiated (Sup-
plementary Figs. S8b, S9). Furthermore, we determined the number of DCX positive cells, a marker expressed 
by neuronal precursor cells and immature  neurons58. More than 97% of control and KO cells were DCX positive, 
indicating unaltered differentiation (Supplementary Figs. S8c, S9). Lastly, we assessed if the number of apoptotic 
or dead cells might be increased in KO by using FACS staining with Annexin V and SYTOX Green Nucleic Acid 
Stain. We did not detect any changes in these regards (Supplementary Figs. S8d, S9). Therefore, the reason for 
slower proliferation of differentiating PHF6 KO cells remained elusive.
We also assessed migration of SK-N-BE (2) cells under normal culture conditions using a wound healing 
assay. PHF6 KO cells migrated significantly slower and filled a significantly smaller area of the wound after 24 h 
than control cells (p value < 0.01) (Fig. 4d).
These observations support a possible role of PHF6 in proper neurite outgrowth and neuron development, 
which might be altered in BFLS.
Figure 4.  PHF6 KO in cells reveals impaired neurite outgrowth, proliferation and migration. (a) Example of 
differentiating control and PHF6 KO cells transfected with mCD8-GFP. The cell with PHF6 KO had a longer 
primary neurite (axon) than the control cell. Scale bar depicts 20 µm. (b) Quantitative analysis of total neurite 
length, number of primary neurites and axon length (longest primary neurite) of day 10 differentiated PHF6 
KO and control cells. PHF6 KO cells had significantly longer protrusions (total neurite length) and significantly 
more primary neurites. Additionally, axon length was also significantly increased in PHF6 KO cells. Of note, 
while control cells developed 1–2 neurites, some of the PHF6 KO cells had up to five neurites. For each cell 
line, at least 15 cells were evaluated per biological replicate. (c) After 8 days of differentiation, PHF6 KO cells 
showed significantly impaired proliferation in comparison to control cells. (d) Scratch assay showing that 
undifferentiated PHF6 KO cells migrated significantly slower than control cells. All experiments were performed 
in biological triplicates, except for the proliferation assay, which was performed in biological duplicates. Error 
bars depict the standard deviation. Asterisks indicate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001).
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Discussion
Variant consequences on protein localisation and structure. PHF6 belongs to the growing list of 
X-chromosomal genes, in which variants not only cause X-chromosomal recessive NDDs in males but also 
severe NDDs in females when occurring de  novo4,59–62. Factors contributing to different manifestation in males 
versus females might include X-inactivation, functional mosaicism due to X-inactivation, localisation and nature 
of variants, different functional consequences of sex specific variants, and dosage related expression  effects4,59–62. 
Although the mutational spectrum for PHF6 includes truncating and missense variants for both genders, there 
are no overlapping variants reported yet occurring in both X-chromosomal recessive BFLS families and de novo 
in females. Additionally, variants identified in females seem to represent the severe end of the mutational spec-
trum. There are more truncating variants than in males, and the only missense variant is located within the 
C-terminal ePHD, while variant localisation in males is more  variable4. It might therefore be speculated that 
variants found in females might have a more severe effect than variants found in males and might be lethal when 
occurring hemizygously. This is supported by the fact that complete knockout of PHF6 is lethal in  mice56,63. 
Such a severe effect would be in line with our observation of complete loss of mutant PHF6 on both mRNA and/
or protein level in fibroblasts of three females, independent from the variant (2-exon duplication, truncating 
variant, missense variant). In a previous study on variants identified in male individuals with BFLS, a hypomor-
phic effect was  discussed56. This is supported by several findings. A mouse model with CRISPR/Cas9 mediated 
knock-in of the specific c.296G>T (p.(Cys99Phe)) variant showed unaltered mRNA expression and only reduced 
protein levels of mutant PHF656. Furthermore, while the only missense variant identified in females is residing in 
the C-terminal ePHD, missense variants identified in males are located in either the N-terminal or the C-termi-
nal ePHD. The N-terminal ePHD mediates the interaction of PHF6 with  UBTF12,14, and the C-terminal ePHD 
interacts with double stranded DNA (dsDNA) through its positively charged  region9. NMR spectra analysis of 
the four missense variants of male origin in the C-terminal ePHD did not reveal a structural impairment, while 
dsDNA binding abilities were still almost completely  abolished9. Whereas structural modelling in our study 
indicated a severe effect on protein structure for variants in the N-terminal ePHD, it is predicted to be less severe 
for male variants in the C-terminal ePHD. In contrast, the female missense variant in the C-terminal ePHD 
appears to have a severe effect on protein structure. This suggests that in males a more severe structural effect on 
the N-terminal ePHD is required to result in a comparable impairment of PHF6 function as from variants in the 
C-terminal ePHD. As a logic implication, a severe alteration in the important C-terminal ePHD might be lethal 
in males and result in a severe NDD in heterozygous females. The association of inherited variants in X-linked 
recessive BFLS families with no or only mild phenotypes in carrier females might therefore be due to a less severe 
effect on protein function. However, we cannot exclude that variants in PHF6 occurring in male individuals also 
result in complete loss of protein, especially those with high destabilizing effects on the N-terminal ePHD.
Though it is debatable—in light of the observations from fibroblasts—if overexpression of mutant PHF6 is a 
suitable model for BFLS, it is interesting to see that there are also differences in the subcellular localisation and 
protein levels depending on the variant occurrence in males or females.
Therefore, in addition to X-inactivation related functional mosaicism, also more severe functional conse-
quences of pathogenic PHF6 variants in females might contribute to their severe and distinct phenotype. This 
suggests a possible genotype–phenotype correlation regarding gender-based localisation and severity of PHF6 
variants.
PHF6 is involved in chromatin/transcriptional regulation. There are several lines of evidence point-
ing to PHF6 acting as a chromatin/transcription regulator, among them its domain  structure2,9, its nuclear 
 localisation8 and co-localisation with  euchromatin8, and its interaction with several chromatin remodelling or 
transcription regulating proteins and  complexes12,13,16,64. Two recent studies used ChIP (chromatin immuno-
precipitation) sequencing to show that PHF6 binds chromatin similar to typical chromatin  remodelers17,18. Fur-
thermore, transcriptional deregulation as a consequence of Phf6 knockdown or knockout was demonstrated in 
the nervous system of two independent mouse  models17,56 and one rat  model12. Using a human, neuron-like cell 
line in our study, we also found a broad deregulation of genes upon KO of PHF6. Deregulated genes significantly 
overlapped with deregulated genes after dosage alterations of known chromatin remodelers or transcription 
factors such as KDM5C, the BAF complex, BMI1 and TCF4, suggesting that PHF6 might act in a similar way. 
Interestingly, all overlapping genes were enriched for genes involved in either neuron generation and differentia-
tion, or even more specific in axon development and guidance and synaptic signalling, proposing a specific role 
for PHF6 in these processes. In detail, the highest overlap was found with deregulated genes after either Kdm5c 
KO in the frontal cortex or Bmi1 KO. Pathogenic variants in KDM5C are associated with a NDD, partly mirror-
ing the phenotype observed in males with  BFLS42–44. Therefore, commonly deregulated genes, most prominently 
involved in synaptic signalling, might contribute to these similarities. BMI1 is a major component of the poly-
comb group complex 1 (PRC1), which is an essential epigenetic repressor of multiple regulatory genes involved 
in embryonic  development48–50,65. This is also in line with a recent study identifying PHF6 as a transcriptional 
repressor of activity-dependent immediate-early  genes18 and other studies discussing repressing  effects9,17. How-
ever, repressing function might only apply for specific pathways, as deregulated genes both in our as well as 
other transcriptome  studies12,17,18,56 indicated both upregulating and downregulating capacities. Furthermore, 
Bmi1 is required for the repression of Hox genes, preserving the undifferentiated state of stem cells and prevent-
ing inappropriate  differentiation50. We also observed an upregulation of Hox genes after PHF6 KO, suggesting a 
potential similar mechanism. Interestingly, deregulated genes upon PHF6 KO also significantly overlapped with 
deregulated genes after KO of BAF (SWI/SNF) complex subunits in mouse (pallium of E17.5 embryos). Variants 
in multiple subunits of the BAF are causative for Coffin–Siris syndrome, a NDD with multiple  anomalies46,47. As 
phenotypic overlap between BFLS in females and CSS has been acknowledged  before5,66,67, commonly deregu-
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lated genes, especially enriched for genes involved in neuron generation, development and differentiation, might 
contribute to the phenotypic similarities between these disorders.
PHF6 is involved in neuron development. Deregulated genes in our study were mainly enriched for 
genes involved in broad processes such as transcriptional and chromatin regulation, but also for more spe-
cific processes such as axon and neuron development. Following-up this observation in neuron-like cells, we 
indeed observed a significantly increased total length of protrusions, an increased number of primary neurites 
and increased axon length. Altered neurite development has been demonstrated in several other NDD models 
before. For example, shRNA mediated knockdown of Kiaa2022 (KIAA2022 [MIM: 300524]), which is impli-
cated in an X-chromosomal NDD in both males and females (MRX98 [MIM: #300912]), in mice resulted in 
longer or shortened apical neurites dependent on the developmental  timepoint68. Also shRNA mediated knock-
down of Ankrd11 (ANKRD11 [MIM: 611192]), of which haploinsufficiency in humans is associated with neu-
rodevelopmental KBG syndrome (MIM: #148050), resulted in an increased number of shortened neurites in a 
mouse  model69. Apart from neurite development also aberrant migration and differentiation of neurons and 
precursor cells can be observed in  NDDs69–73. During radial migration, pyramidal neurons undergo a transition 
from multipolar to bipolar morphology in the intermediate zone (reviewed in 74). Impairment of this transition 
process in cortical pyramidal neurons and subsequently radial migration defects were described for the Ankrd11 
mouse  model69. In accordance, we observed significantly slower migration of SK-N-BE (2) cells after PHF6 KO 
compared to controls. In combination with the observation of an increased number of neurites this might be 
in line with a disturbed transition from multi- to bipolar neurons. Impaired migration has been discussed in 
the context with BFLS  before12. An RNAi based knockdown of Phf6 in the developing mouse cerebral cortex at 
E14 showed impaired migration of cortical neurons as well as an increased number of multipolar neurons and 
a concomitantly reduced number of bipolar  neurons12. However, in another mouse model carrying a patient 
specific Phf6 variant (p.Cys99Phe), no migration defects were  reported56. Of note, there is also a report on two 
adult female individuals with the identical de novo duplication of exons 4 and 5 in PHF6 and presenting with 
seizures, in whom MRI anomalies were described that would be compatible with malformations of cortical 
development based on abnormal neuronal  migration75. Furthermore, PHF6 is directly targeted and suppressed 
by miR-128 in the developing cortex. Their interaction is critical for proper migration and dendritic outgrowth 
of upper layer  neurons76.
Apart from altered neurite outgrowth and migration we also observed altered proliferation in our cell model, 
another anomaly often observed in  NDDs73. Differentiating SK-N-BE (2) cells after PHF6 KO proliferated sig-
nificantly slower than control cells, while SK-N-BE (2) cells under normal cell culture conditions did not exhibit 
changes Previous studies showed that stable knockdown of PHF6 in HeLa cells under normal cell culture con-
ditions resulted in decreased cell proliferation starting on day  five14, while CRISPR/Cas9 mediated Phf6 KO 
in B-ALL cells did not show any proliferation  changes17, and Phf6 KO in hematopoietic stem cells resulted in 
better  growth77. This might indicate that the effect of PHF6 loss on proliferation might be cell type specific. For 
differentiating SK-N-BE (2) cells, we investigated if underlying mechanisms might be apoptosis, cell death, 
accelerated differentiation or cell cycle changes. A role of PHF6 in cell cycle regulation has been controversially 
 discussed14,15,17,19. We could not detect changes in cell cycle regulation or any of these other processes, leaving 
the reason for the proliferation defect unclear.
Taken together, our observations suggest that PHF6 might act as a context-specific epigenetic activator/
repressor and is required for correct migration, proliferation and development of neurons. Also dependent on 
the severity of variants (males versus females), impairment of these processes might contribute to the neurode-
velopmental and cognitive dysfunction in BFLS.
Material and methods
Structural modelling. The structural effects of variants located in the C-terminal ePHD were assessed 
based on the crystal structure of this domain (PDB code:  4NN29). This structure also served as a template to 
model the N-terminal ePHD, which exhibits 47% sequence identity to the C-terminal ePHD. Modelling was 
performed with  HHpred78 and  Modeller79. The structural effect of the variants was assessed using  VIPUR30, 
which is designed to distinguish between neutral and deleterious protein variants by modelling their effect on 
the three-dimensional protein structure.
Cell lines. This study was approved by the ethical review board of the University Erlangen-Nuremberg, and 
informed consent was obtained from healthy control individuals, parents (underaged participants) or legal 
guardians (affected adult participants). The work described here was conducted in accordance with relevant 
guidelines and regulations.
Skin fibroblasts were obtained from three previously published female  individuals4 with de novo variants in 
PHF6. HEK-293, SK-N-BE (2) cells and fibroblasts were cultured at 37 °C and 5%  CO2 under sterile conditions. 
For differentiation of neuroblastoma SK-N-BE (2) cells into neuron-like cells, they were seeded into 6-well plates 
and differentiated for 10 days using 10 µM all-trans retinoic acid and 25 µM caffeic acid. Medium was changed 
every 2–3 days (protocol was adapted  from80).
Protein, RNA and DNA analysis. Human PHF6 was amplified from cDNA derived from whole blood 
and cloned into a pCR 2.1-TOPO vector (Thermo Fisher Scientific). After site-directed mutagenesis using a 
modified version of the QuikChange Site-Directed Mutagenesis protocol (Stratagene), wildtype and mutant 
PHF6 cDNAs were transferred into an N-terminal HA-tagged CMV expression vector. C-terminal myc-tagged 
UBE3A in a pCMV3 expression vector was used as transfection control.
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For immunofluorescence experiments, cells were grown on poly-lysine coated coverslips and transiently 
transfected with the plasmids using jetPrime (Polyplus-transfection) following manufacturer’s instructions. Cells 
were fixated with 4% paraformaldehyde in PBS for 10 min at room temperature (RT) or with MetOH + EGTA 
for 10 min at − 20 °C 24 or 48 h post transfection. Cells were stained with rabbit polyclonal anti-PHF6 antibody 
(HPA001023, Sigma-Aldrich, 1:50), or rabbit anti-HA (H6908, Sigma-Aldrich, 1:75) and mouse monoclonal 
anti-Nucleolin antibody (39-6400, Thermo Fisher Scientific, 1:200), and with Alexa Fluor 488 goat anti-mouse 
(A11001, Thermo Fisher Scientific, 1:1,500), and/or Alexa Fluor 546 donkey anti-rabbit (A10040, Thermo Fisher 
Scientific, 1:1,500), and DAPI (SERVA, 1:25,000) for nuclei counterstaining. Cells were analyzed with a Zeiss 
Axio Imager Z2 Apotome microscope with a 63 × objective. For analysis of patient fibroblasts, at least 63 cells 
per cell line were analyzed, and the number of PHF6 expressing cells was counted. For analysis of HA-tagged 
mutant and wildtype PHF6, at least 40 cells per construct were analyzed.
RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN) following manufacturer’s instructions. 
DNase digestion was performed on-column with the RNase-free DNase kit (QIAGEN). Reverse transcription 
of RNA into cDNA was performed using the SuperScript II reverse transcriptase (Thermo Fisher Scientific).
Genomic DNA (gDNA) was extracted from cells using the DNeasy Blood & Tissue Kit (QIAGEN) following 
manufacturer’s instructions.
For analysis of patient variants in PHF6 on RNA and gDNA level, Exon 9 was amplified (primer sequences 
exon 9: F: tagatgtcagacctgggatgg; R: ttggatggatgaatgctaatc) and sequenced.
For protein analysis, cells were lysed in Lysis Puffer (0.01 M Tris, 0.15 M NaCl, 1%Triton-X, 1%Protease 
Inhibitors, pH 7.5) and frozen for 1 h at − 80 °C.
For western immunoblotting, the Mini PROTEAN TGX stain free electrophorese system (Bio-Rad, 1658005) 
in combination with the Trans-Blot Turbo Transfer System (Bio-Rad, 1704150) was used. After blocking, mem-
brane was incubated with either rabbit polyclonal anti-PHF6 (HPA001023, Sigma-Aldrich, 1:200), mouse mono-
clonal anti-PHF6 (sc-365237, Santa Cruz Biotechnology, 1:500), mouse anti-tubulin (ab7291, abcam, 1:10,000), 
mouse anti-myc (M4439, Sigma-Aldrich, 1:5,000) or rabbit anti-HA (H6908, Sigma-Aldrich, 1:500) antibody 
for 1.5 h at RT or overnight at 4 °C. Whole protein or alpha-tubulin were used as loading controls. C-terminal 
myc-tagged UBE3A was used as transfection control. Secondary, HRP-conjugated antibody (goat anti-rabbit, 
170-6515, Bio-Rad, 1:10,000; or goat anti-mouse, ab97023, abcam, 1:10,000) was applied for 1 h. Blots were 
stained with SuperSignal West Femto Maximum Sensitivity Substrate, scanned using the ChemiDoc Imaging 
System (Bio-Rad, 17001401), and analyzed using the Image Lab software version 6.0.0 (Bio-Rad). Mutant HA-
tagged PHF6 was normalized using transfection control UBE3A (myc-tagged).
CRISPR/Cas9 mediated PHF6 KO. SK-N-BE (2) cells were subjected to CRISPR/Cas9 mediated KO using 
the GeneArt CRISPR Nuclease Vector Kit (Life Technologies). PHF6 specific crRNA sequences were created 
using the CRISPR Targets Track from UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly. 
Two crRNAs were designed, targeting exon 2 or 9, respectively. The guide sequence, efficiency as well as potential 
off targets can be found in Supplementary Table S1 and S2. For completion of the GeneArt CRISPR Nuclease 
Vector, the crRNA was cloned into the vector following manufacturer’s instructions. Knockout was performed 
following manufacturer’s instructions. To achieve transfected single cell colonies, after 24 h transfected cells were 
resuspended in 1 × PBS supplemented with 2% FCS and 2 mM EDTA and sorted into 96-wells using FACS and 
OFP as a fluorescent marker. Single cell colonies were grown until confluency and transferred into one well of a 
six well plate. Genomic DNA was extracted and sequenced to assess for gene disrupting variants (Supplementary 
Fig. S4a). Positive clones were validated using western blotting (Supplementary Fig. S4b–d).
RNA sequencing and transcriptome analysis. RNA sequencing was executed in-house at the NGS core 
unit of the Medical Faculty of the FAU Erlangen. The TruSeq Stranded mRNA LT Sample Prep Kit (illumina, San 
Diego, CA) was used for library preparation. Libraries were subjected to single-end sequencing (101 bp) on a 
HiSeq-2500 platform (illumina, San Diego, CA, USA). The obtained reads were converted to .fastq format and 
demultiplexed using bcl2fastq v2.17.1.14. Quality filtering was performed using cutadapt v. 1.1581; then reads 
were mapped against the human reference genome (Ensembl GRCh37, release 87) using the STAR aligner v. 
2.5.4a82, and a STAR genome directory created by supplying the Ensembl gtf annotation file (release 87). Read 
counts per gene were obtained using featureCounts program v. 1.6.183 and the Ensembl gtf annotation file.
Following analyses were performed using R version 3.5.084. In particular, differential expression analysis and 
principal component analysis (PCA) was performed with the DESeq2 package v.1.20.085. Heatmap was created 
using the pheatmap package v.1.0.12 applying the standard settings (complete linkage method for hierarchical 
clustering for both columns and rows, scaling for rows)86.
Enrichment analysis was performed using four already published data  sets36–39 and one in house so far 
unpublished list of deregulated genes after TCF4 dosage alterations from RNA sequencing and transcriptome 
analysis of RNA from peripheral blood, collected and extracted with the PaxGene system (PreAnalytiX, BD and 
QIAGEN, Hombrechtikon, Switzerland) from three individuals with variants in TCF4 (Supplementary Table S1). 
RNA sequencing was performed as described above. The KDM5C deregulated gene dataset was retrieved from 
a Kdm5c KO mouse model, where the authors dissected the amygdala and the frontal cortex from three adult 
mice for each genotype (KO/WT) and performed RNA  sequencing36. The BAF-complex deregulated gene data-
set was retrieved from a conditional dKO Baf155/Baf170 mouse model where both genes where knocked out 
in late cortical neurogenesis. RNA was extracted from the pallium of E17.5 embryos and RNA sequencing was 
 performed37. The BMI1 deregulated gene dataset was retrieved from adult brain tissue from a Bmi1 KO mouse 
 model38. The TCF4 deregulated gene dataset was retrieved from TCF4 KD SH-SY5Y neuroblastoma  cells39. 
Firstly, deregulated genes in mice were converted to human gene IDs using  BioMart87. A common background 
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was generated by using all genes with a base mean > 2 (if applicable) that were present in both data sets. Next, 
deregulated genes present in shared background were computed. Lastly, overlap of these deregulated genes was 
computed. Lists can be found in Supplementary Table S1. Testing for statistical significance was performed using 
hypergeometric testing and correcting for multiple testing using the Benjamini–Hochberg procedure. GO term 
analysis was performed on overlapping genes.
For comparison with confirmed ID genes (SysID  database54, June 2020), the number of confirmed ID genes 
present in SK-N-BE (2) transcriptome data was analyzed and the overlap with deregulated genes was computed. 
Statistical testing was performed using hypergeometric testing. GO term analysis was performed on overlapping 
genes.
Deregulated genes were compared with RNA sequencing datasets from two different  studies18,56. Data was 
processed as described above for enrichment analysis.
Measurement of neurites. For neurite analysis SK-N-BE (2) cells were transfected with 1 µg of mCD8-
GFP using jetPRIME (Polyplus-transfection) following manufacturer’s instructions on day eight of differentia-
tion. 24 h post transfection medium was changed. Cells were subjected to immunofluorescence analysis at dif-
ferentiation day 10 as described above using only DAPI as counterstaining.
Cells were analyzed with a Zeiss Axio Imager Z2 Apotome microscope. Primary and secondary neurite length 
was measured using the NeuronJ  plugin88 in  Fiji89 and respective number was counted. Three PHF6 KO and three 
control cell lines were evaluated, for each line at least 30 cells were measured. The experiment was performed in 
biological triplicates. Data was tested for normality using the Kolmogorov–Smirnov test. Testing for statistical 
significance was performed using a two-tailed t test.
XTT assay. Proliferation of undifferentiated and differentiating cells was assessed using the CyQUANT XTT 
Cell Viability Assay (invitrogen). Three PHF6 KO and three control cell lines were seeded in 96-well plates and 
either kept in normal medium for 4 days or differentiated for 10 days. Every day, four wells per cell line were 
treated with the XTT reagent following manufacturer’s instructions and incubated for 4 h. The color change 
was measured using a plate reader at wave length 660 nm and 450 nm. The specific absorbance of each well was 
determined using following formula: Specific Absorbance = [Abs450 nm(Test) −Abs450 nm(Blank)] −Abs660 
nm(Test). The experiment was performed in biological duplicates and technical quadruplicates. Data was tested 
for normality using the Kolmogorov–Smirnov test. Testing for statistical significance was performed using a 
two-tailed t test.
Wound healing assay. Migration of PHF6 KO and control cells was assessed using four well culture inserts 
(ibidi) following manufacturer’s instructions. SK-N-BE (2) cells were seeded into each well of the culture inserts, 
which were removed after 24 h. Resulting cell gaps were photographed every 4 h up to 24 h. The growth area 
was measured using the Wound healing  tool90 on  Fiji89. The experiment was performed in biological triplicates 
using four control cell lines and eight PHF6 KO cell lines. Data was tested for normality using the Kolmogorov–
Smirnov test. Testing for statistical significance was performed using a two-tailed t test.
Data availability
OMIM, https ://www.omim.org/. Gene Ontology, https ://geneo ntolo gy.org/. SysID database, https ://sysid .cmbi.
umcn.nl/.
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